Olopatadine is an
antihistamine and
mast cell stabilizer used for treating
allergic conjunctivitis.
Olopatadine 0.7% has been recently approved for daily dosing in the US, which supersedes the previously approved 0.2% strength. The objective of this analysis was to characterize patients who have better
itching relief at 24 h when taking
olopatadine 0.7% treatment instead of
olopatadine 0.2% (in terms of proportions of responses) and relate this to the severity of baseline
itching as an indirect metric of a patient's sensitivity to
antihistamines. A differential odds model was developed using data from two conjunctival
allergen challenge (CAC) studies to characterize individual-level and population-level response to ocular
itching following
olopatadine treatment and the data was analyzed retrospectively. This modeling analysis was designed to predict 24 h ocular
itching scores and to quantify the differences in 24 h
itching relief following treatment with
olopatadine 0.2% versus 0.7% in patients with moderate-to-high baseline
itching. A one-compartment kinetic-pharmacodynamic Emax model was used to determine the effect of
olopatadine. Impact of baseline
itching severity, vehicle effect and the
drug effect on the overall
itching scores post-treatment were explicitly incorporated in the model. The model quantified trends observed in the clinical data with regards to both mean scores and the proportions of patients responding to
olopatadine treatment. The model predicts a higher proportion of patients in the
olopatadine 0.7% versus 0.2% group will experience relief within 24 h. This prediction was confirmed with retrospective clinical data analysis. The number of
allergy patients relieved with
olopatadine 0.7% increased with higher baseline
itching severity scores, when compared to
olopatadine 0.2%.